ArticleBreast cancer research and treatment2013

Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).

Edith A Perez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.